Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan F List

Showing results (201-210 of 212) with videos related to

Pageof 22
Sort By:
Blood|June 17, 2022
A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventionsTae-Hoon Shin, Yifan Zhou, Shirley Chen, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
The New England Journal of Medicine|January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesPierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.
Blood Reviews|March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
Leukemia|January 13, 2019
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroupsDetlef Haase, Kristen E Stevenson, Donna Neuberg, et al.
Leukemia|October 20, 2022
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic SyndromesAmer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, et al.
Blood Reviews|September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.
Blood|March 27, 2025
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statementUma Borate, Kelly Pugh, Allyson Waller, et al.
Blood Advances|October 19, 2022
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDSMaximilian Stahl, Omar Abdel-Wahab, Andrew H Wei, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 25, 2024
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])Fnu Aakash, Savanah D Gisriel, Amer M Zeidan, et al.
Pageof 22

Showing results (201-210 of 212) with videos related to

Sort By:
Pageof 22
Blood|June 17, 2022
A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventionsTae-Hoon Shin, Yifan Zhou, Shirley Chen, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
The New England Journal of Medicine|January 9, 2020
Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesPierre Fenaux, Uwe Platzbecker, Ghulam J Mufti, et al.
Blood Reviews|March 18, 2023
Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)Jan Philipp Bewersdorf, Zhuoer Xie, Rafael Bejar, et al.
Leukemia|January 13, 2019
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroupsDetlef Haase, Kristen E Stevenson, Donna Neuberg, et al.
Leukemia|October 20, 2022
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic SyndromesAmer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, et al.
Blood Reviews|September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.
Blood|March 27, 2025
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statementUma Borate, Kelly Pugh, Allyson Waller, et al.
Blood Advances|October 19, 2022
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDSMaximilian Stahl, Omar Abdel-Wahab, Andrew H Wei, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 25, 2024
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])Fnu Aakash, Savanah D Gisriel, Amer M Zeidan, et al.
Pageof 22